Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Takafumi Sato, Kenji Yamawaki
Clinical Infectious Diseases (2019) Vol. 69, Iss. Supplement_7, pp. S538-S543
Open Access | Times Cited: 253

Showing 1-25 of 253 citing articles:

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti, Roger Echols, Yuko Matsunaga, et al.
The Lancet Infectious Diseases (2020) Vol. 21, Iss. 2, pp. 226-240
Closed Access | Times Cited: 597
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
Clinical Infectious Diseases (2019) Vol. 69, Iss. Supplement_7, pp. S565-S575
Open Access | Times Cited: 519
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives
Marco Terreni, Marina Taccani, Massimo Pregnolato
Molecules (2021) Vol. 26, Iss. 9, pp. 2671-2671
Open Access | Times Cited: 399
Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter
Sameer Dhingra, Nor Azlina A. Rahman, Ed Peile, et al.
Frontiers in Public Health (2020) Vol. 8
Open Access | Times Cited: 248
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed
Mark S. Butler, Valeria Gigante, Hatim Sati, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 3
Open Access | Times Cited: 197
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Yoshinori Yamano
Clinical Infectious Diseases (2019) Vol. 69, Iss. Supplement_7, pp. S544-S551
Open Access | Times Cited: 163
Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
Loukas Kakoullis, Eleni Papachristodoulou, Paraskevi Chra, et al.
Antibiotics (2021) Vol. 10, Iss. 4, pp. 415-415
Open Access | Times Cited: 158
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
Stamatis Karakonstantis, Maria Rousaki, Evangelos I. Kritsotakis
Antibiotics (2022) Vol. 11, Iss. 6, pp. 723-723
Open Access | Times Cited: 153
Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems
Stamatis Karakonstantis, Evangelos I. Kritsotakis, Achilleas Gikas
Infection (2020) Vol. 48, Iss. 6, pp. 835-851
Open Access | Times Cited: 140
Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review
Mihret Tilahun, Yeshimebet Kassa, Alemu Gedefie, et al.
Infection and Drug Resistance (2021) Vol. Volume 14, pp. 4363-4374
Open Access | Times Cited: 140
Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race
Aleksandra Baran, Aleksandra Kwiatkowska, Leszek Potocki
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5777-5777
Open Access | Times Cited: 129
The importance of sulfur-containing motifs in drug design and discovery
Muhamad Mustafa, Jean‐Yves Winum
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 5, pp. 501-512
Closed Access | Times Cited: 120
Fighting antibiotic resistance—strategies and (pre)clinical developments to find new antibacterials
Sebastian Walesch, Joy Birkelbach, Gwenaëlle Jézéquel, et al.
EMBO Reports (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 112
Alternatives Therapeutic Approaches to Conventional Antibiotics: Advantages, Limitations and Potential Application in Medicine
Hiba Alaoui Mdarhri, Rachid Benmessaoud, Houda Yacoubi, et al.
Antibiotics (2022) Vol. 11, Iss. 12, pp. 1826-1826
Open Access | Times Cited: 70
Design and Synthesis of Novel Antimicrobial Agents
Zeinab Breijyeh, Rafik Karaman
Antibiotics (2023) Vol. 12, Iss. 3, pp. 628-628
Open Access | Times Cited: 68
The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy
Aura Rusu, I. Moga, Livia Uncu, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2554-2554
Open Access | Times Cited: 53
Emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability
Shikha Sharma, Abhishek Chauhan, Anuj Ranjan, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 33
Sophisticated natural products as antibiotics
Kim Lewis, Richard Lee, Heike Brötz‐Oesterhelt, et al.
Nature (2024) Vol. 632, Iss. 8023, pp. 39-49
Closed Access | Times Cited: 25
Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis
Lorenzo Onorato, Ilaria de Luca, Caterina Monari, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106113-106113
Open Access | Times Cited: 18
Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species
Gabriele Bianco, Matteo Boattini, Sara Comini, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 3, pp. 559-566
Closed Access | Times Cited: 15
ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro
Lejla Daruka, Márton Simon Czikkely, Petra Szili, et al.
Nature Microbiology (2025)
Open Access | Times Cited: 2
Cefiderocol AST in a real-life Klebsiella pneumoniae collection: challenges in the ATU range
Juan Antonio Castillo-Polo, Marta Hernández-García, Ainhize Maruri-Aransolo, et al.
Journal of Antimicrobial Chemotherapy (2025)
Closed Access | Times Cited: 2
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Patricia J. Simner, Robin Patel
Journal of Clinical Microbiology (2020) Vol. 59, Iss. 1
Open Access | Times Cited: 116
Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics
Phillip E. Klebba, Salete M. Newton, David A. Six, et al.
Chemical Reviews (2021) Vol. 121, Iss. 9, pp. 5193-5239
Open Access | Times Cited: 97
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii
Laurent Poirel, Mustafa Sadek, Patrice Nordmann
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 10
Open Access | Times Cited: 94
Page 1 - Next Page

Scroll to top